gsk-3β inhibitor ii Search Results


gsk3β inhibitor  (MedChemExpress)
93
MedChemExpress gsk3β inhibitor
<t>GSK3β</t> was enriched in TAMs of tumors based on scRNA-seq. (A, B) UMAP map identifies 6 cell clusters that define the classification of specific gene signatures, including B cells, CAFs, malignant cells, T cells, TAMs, TECs based on GSE151530. (C) The point diagram showing expression of GSK3β in TAMs. Baselines, first, second indicates specimens collected at different time points. (D, E) UMAP map identifies 12 cell clusters based on GSE164522. (F) The violin plot showing expression of GSK3β in TAMs. TAMs, tumor-associated macrophages; TECs, thymic epithelial cells.
Gsk3β Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gsk3β inhibitor/product/MedChemExpress
Average 93 stars, based on 1 article reviews
gsk3β inhibitor - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


GSK3β was enriched in TAMs of tumors based on scRNA-seq. (A, B) UMAP map identifies 6 cell clusters that define the classification of specific gene signatures, including B cells, CAFs, malignant cells, T cells, TAMs, TECs based on GSE151530. (C) The point diagram showing expression of GSK3β in TAMs. Baselines, first, second indicates specimens collected at different time points. (D, E) UMAP map identifies 12 cell clusters based on GSE164522. (F) The violin plot showing expression of GSK3β in TAMs. TAMs, tumor-associated macrophages; TECs, thymic epithelial cells.

Journal: Journal for Immunotherapy of Cancer

Article Title: Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy

doi: 10.1136/jitc-2022-005655

Figure Lengend Snippet: GSK3β was enriched in TAMs of tumors based on scRNA-seq. (A, B) UMAP map identifies 6 cell clusters that define the classification of specific gene signatures, including B cells, CAFs, malignant cells, T cells, TAMs, TECs based on GSE151530. (C) The point diagram showing expression of GSK3β in TAMs. Baselines, first, second indicates specimens collected at different time points. (D, E) UMAP map identifies 12 cell clusters based on GSE164522. (F) The violin plot showing expression of GSK3β in TAMs. TAMs, tumor-associated macrophages; TECs, thymic epithelial cells.

Article Snippet: In the process of differentiation from M0 cells to TAM cells, we divided them into different groups, adding PBS(Phosphate Buffered Saline), GSK3β inhibitor (MCE, USA) and escitalopram (GLPBIO, USA) respectively, to observe the difference of TAMs obtained in different groups.

Techniques: Expressing

Macrophage GSK3β deficiency inhibited the progression of HCC. (A) Images of subcutaneous tumors in each group (GSK3β fl/fl Lyz2 cre/+ , GSK3β fl/fl ). (B, C) Weight and volume analysis of subcutaneous tumors in the respective groups. (D, E) Immunohistochemistry results of CD8, Ki67, PD-L1 and PD1 expression in the respective groups. (F) The growth curves of HCC cells were plotted after cultured with TAMs added GSK3β inhibitor based on CCK-8 assays. (G) EdU assays were performed to assess cell proliferation of LM3 and YY8103 cell lines cultured with TAM added GSK3β inhibitor. (H) Transwell experiment was adopted to assess cell invasion and migration of HCC cells incubated with TAM added GSK3β inhibitor. (I) Wound healing assays were used to assess cell migration of HCC cells after cultured with TAM added GSK3β inhibitor. *p＜0.05, **p<0.01, ***p<0.001, ****p<0.001. HCC, hepatocellular carcinoma; TAM, tumor-associated macrophage.

Journal: Journal for Immunotherapy of Cancer

Article Title: Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy

doi: 10.1136/jitc-2022-005655

Figure Lengend Snippet: Macrophage GSK3β deficiency inhibited the progression of HCC. (A) Images of subcutaneous tumors in each group (GSK3β fl/fl Lyz2 cre/+ , GSK3β fl/fl ). (B, C) Weight and volume analysis of subcutaneous tumors in the respective groups. (D, E) Immunohistochemistry results of CD8, Ki67, PD-L1 and PD1 expression in the respective groups. (F) The growth curves of HCC cells were plotted after cultured with TAMs added GSK3β inhibitor based on CCK-8 assays. (G) EdU assays were performed to assess cell proliferation of LM3 and YY8103 cell lines cultured with TAM added GSK3β inhibitor. (H) Transwell experiment was adopted to assess cell invasion and migration of HCC cells incubated with TAM added GSK3β inhibitor. (I) Wound healing assays were used to assess cell migration of HCC cells after cultured with TAM added GSK3β inhibitor. *p＜0.05, **p<0.01, ***p<0.001, ****p<0.001. HCC, hepatocellular carcinoma; TAM, tumor-associated macrophage.

Article Snippet: In the process of differentiation from M0 cells to TAM cells, we divided them into different groups, adding PBS(Phosphate Buffered Saline), GSK3β inhibitor (MCE, USA) and escitalopram (GLPBIO, USA) respectively, to observe the difference of TAMs obtained in different groups.

Techniques: Immunohistochemistry, Expressing, Cell Culture, CCK-8 Assay, Migration, Incubation

GSK3β was enriched in TAMs of tumors in the primary resistance of anti-PD1 immunotherapy for HCC. (A–C) The immunofluorescence was used to verify the different CD163+GSK3β+expression in TAMs between non-responder to anti-PD1 treatment group and responder group. (D–F) Immunohistochemistry results of GSK3β and PD-L1 expression in the non-responder to anti-PD1 treatment group and responder group. **p<0.01. HCC, hepatocellular carcinoma; TAMs, tumor-associated macrophages.

Journal: Journal for Immunotherapy of Cancer

Article Title: Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy

doi: 10.1136/jitc-2022-005655

Figure Lengend Snippet: GSK3β was enriched in TAMs of tumors in the primary resistance of anti-PD1 immunotherapy for HCC. (A–C) The immunofluorescence was used to verify the different CD163+GSK3β+expression in TAMs between non-responder to anti-PD1 treatment group and responder group. (D–F) Immunohistochemistry results of GSK3β and PD-L1 expression in the non-responder to anti-PD1 treatment group and responder group. **p<0.01. HCC, hepatocellular carcinoma; TAMs, tumor-associated macrophages.

Article Snippet: In the process of differentiation from M0 cells to TAM cells, we divided them into different groups, adding PBS(Phosphate Buffered Saline), GSK3β inhibitor (MCE, USA) and escitalopram (GLPBIO, USA) respectively, to observe the difference of TAMs obtained in different groups.

Techniques: Immunofluorescence, Expressing, Immunohistochemistry

Macrophage GSK3β deficiency enhanced the sensitivity of anti-PD1 immunotherapy for HCC by decreasing PD-L1 ubiquitination. (A) The ubiquitination expression of PD-L1 via co-immunoprecipitation. (B) Coimmunoprecipitation assays showed an interaction between GSK3β and PD-L1 in 293 T cell. (C) Immunofluorescence staining assays of GSK3β and PD-L1 in 293 T cells observed by confocal microscopy. (D) There were 31 cell clusters in total, which were defined in the respective groups. (E) The histogram showing the number of the respective cell clusters in different groups by mass cytometry. (F) TSNE plot showing distribution of 31 cell clusters. (G) TSNE plot showing distribution of PD1, TIGIT and CTLA4 in two groups. The histogram showing the number of PD1+, TIGIT+ and CTLA4+ cell clusters in different groups. HCC, hepatocellular carcinoma; TSNE: t-distributed stochastic neighbor embedding; TIGIT: T cell immunoreceptor with Ig and ITIM domains.

Journal: Journal for Immunotherapy of Cancer

Article Title: Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy

doi: 10.1136/jitc-2022-005655

Figure Lengend Snippet: Macrophage GSK3β deficiency enhanced the sensitivity of anti-PD1 immunotherapy for HCC by decreasing PD-L1 ubiquitination. (A) The ubiquitination expression of PD-L1 via co-immunoprecipitation. (B) Coimmunoprecipitation assays showed an interaction between GSK3β and PD-L1 in 293 T cell. (C) Immunofluorescence staining assays of GSK3β and PD-L1 in 293 T cells observed by confocal microscopy. (D) There were 31 cell clusters in total, which were defined in the respective groups. (E) The histogram showing the number of the respective cell clusters in different groups by mass cytometry. (F) TSNE plot showing distribution of 31 cell clusters. (G) TSNE plot showing distribution of PD1, TIGIT and CTLA4 in two groups. The histogram showing the number of PD1+, TIGIT+ and CTLA4+ cell clusters in different groups. HCC, hepatocellular carcinoma; TSNE: t-distributed stochastic neighbor embedding; TIGIT: T cell immunoreceptor with Ig and ITIM domains.

Article Snippet: In the process of differentiation from M0 cells to TAM cells, we divided them into different groups, adding PBS(Phosphate Buffered Saline), GSK3β inhibitor (MCE, USA) and escitalopram (GLPBIO, USA) respectively, to observe the difference of TAMs obtained in different groups.

Techniques: Expressing, Immunoprecipitation, Staining, Confocal Microscopy, Mass Cytometry

The sensitivity of anti-PD1 immunotherapy in HCC was increased in GSK3β fl/fl Lyz2 cre/+ mice. (A) Schematic diagram of establishment of mouse subcutaneous tumor model in each group. (B) Images of subcutaneous tumors in each group. (C, D) Analysis of subcutaneous tumors in the respective groups. (E, F) Immunohistochemistry results of CD8, Ki67, PD-L1 and PD1 expression in the respective groups. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. ns indicated no significant different. HCC, hepatocellular carcinoma.

Journal: Journal for Immunotherapy of Cancer

Article Title: Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy

doi: 10.1136/jitc-2022-005655

Figure Lengend Snippet: The sensitivity of anti-PD1 immunotherapy in HCC was increased in GSK3β fl/fl Lyz2 cre/+ mice. (A) Schematic diagram of establishment of mouse subcutaneous tumor model in each group. (B) Images of subcutaneous tumors in each group. (C, D) Analysis of subcutaneous tumors in the respective groups. (E, F) Immunohistochemistry results of CD8, Ki67, PD-L1 and PD1 expression in the respective groups. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. ns indicated no significant different. HCC, hepatocellular carcinoma.

Article Snippet: In the process of differentiation from M0 cells to TAM cells, we divided them into different groups, adding PBS(Phosphate Buffered Saline), GSK3β inhibitor (MCE, USA) and escitalopram (GLPBIO, USA) respectively, to observe the difference of TAMs obtained in different groups.

Techniques: Immunohistochemistry, Expressing

The expression of CD14 + GSK3β + cells from PBMC could noninvasively predict anti-PD1 sensitivity in HCC patients. (A) There were 32 cell clusters in total, which were defined in the respective groups.(B) TSNE plot showing distribution of 32 cell clusters. (C) TSNE diagram showing distribution of cell clusters in the anti-PD1 sensitive and non-sensitive group samples. (D) The histogram showing the number of the respective cell clusters in the anti-PD1 sensitive and non-sensitive groups by mass cytometry. (E) The histogram showing the expression of CD14+GSK3β+ cell in the anti-PD1 sensitive and non-sensitive groups. (F–G) PBMCs were collected from 10 sensitive and 9 insensitive anti-PD1 HCC patients, and the expression of CD14 and GSK3β was measured by flow cytometry. *p＜0.05. HCC, hepatocellular carcinoma; PBMC, peripheral blood mononuclear cell.

Journal: Journal for Immunotherapy of Cancer

Article Title: Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy

doi: 10.1136/jitc-2022-005655

Figure Lengend Snippet: The expression of CD14 + GSK3β + cells from PBMC could noninvasively predict anti-PD1 sensitivity in HCC patients. (A) There were 32 cell clusters in total, which were defined in the respective groups.(B) TSNE plot showing distribution of 32 cell clusters. (C) TSNE diagram showing distribution of cell clusters in the anti-PD1 sensitive and non-sensitive group samples. (D) The histogram showing the number of the respective cell clusters in the anti-PD1 sensitive and non-sensitive groups by mass cytometry. (E) The histogram showing the expression of CD14+GSK3β+ cell in the anti-PD1 sensitive and non-sensitive groups. (F–G) PBMCs were collected from 10 sensitive and 9 insensitive anti-PD1 HCC patients, and the expression of CD14 and GSK3β was measured by flow cytometry. *p＜0.05. HCC, hepatocellular carcinoma; PBMC, peripheral blood mononuclear cell.

Article Snippet: In the process of differentiation from M0 cells to TAM cells, we divided them into different groups, adding PBS(Phosphate Buffered Saline), GSK3β inhibitor (MCE, USA) and escitalopram (GLPBIO, USA) respectively, to observe the difference of TAMs obtained in different groups.

Techniques: Expressing, Mass Cytometry, Flow Cytometry

Escitalopram reduced tumor growth in mice and increased the efficacy of anti-PD1 treatment against HCC. (A) Images of subcutaneous tumors in each group (PBS, GSK3β inhibitor, anti-PD1, GSK3β inhibitor+ anti-PD1). (B, C) Analysis of subcutaneous tumors in the respective groups. (D, E) Immunohistochemistry results of CD8, Ki67, PD-L1 and PD1 expression in the respective groups. (F) Images of subcutaneous tumors in each group (PBS, escitalopram, anti-PD1, and escitalopram+anti-PD1). (G, H) Analysis of subcutaneous tumors in the respective groups. (I) Pattern diagram showing that macrophage GSK3β deficiency inhibits the development of HCC and enhances the sensitivity of anti-PD1 immunotherapy. *p＜0.05, **p<0.01, ***p<0.001. ****p<0.0001. ns indicated no significant different. HCC, hepatocellular carcinoma; PBS, phosphate buffered saline; TAM, tumor-associated macrophage.

Journal: Journal for Immunotherapy of Cancer

Article Title: Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy

doi: 10.1136/jitc-2022-005655

Figure Lengend Snippet: Escitalopram reduced tumor growth in mice and increased the efficacy of anti-PD1 treatment against HCC. (A) Images of subcutaneous tumors in each group (PBS, GSK3β inhibitor, anti-PD1, GSK3β inhibitor+ anti-PD1). (B, C) Analysis of subcutaneous tumors in the respective groups. (D, E) Immunohistochemistry results of CD8, Ki67, PD-L1 and PD1 expression in the respective groups. (F) Images of subcutaneous tumors in each group (PBS, escitalopram, anti-PD1, and escitalopram+anti-PD1). (G, H) Analysis of subcutaneous tumors in the respective groups. (I) Pattern diagram showing that macrophage GSK3β deficiency inhibits the development of HCC and enhances the sensitivity of anti-PD1 immunotherapy. *p＜0.05, **p<0.01, ***p<0.001. ****p<0.0001. ns indicated no significant different. HCC, hepatocellular carcinoma; PBS, phosphate buffered saline; TAM, tumor-associated macrophage.

Article Snippet: In the process of differentiation from M0 cells to TAM cells, we divided them into different groups, adding PBS(Phosphate Buffered Saline), GSK3β inhibitor (MCE, USA) and escitalopram (GLPBIO, USA) respectively, to observe the difference of TAMs obtained in different groups.

Techniques: Immunohistochemistry, Expressing, Saline